Health Care • Biotechnology: Pharmaceutical Preparations
$40.70 ▼ -1.39
(-3.30%)
MKT CAP: $49.05B • VOL: 10.59M
52W L $20 52W H $43
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$34
MEDIAN
$46
MEAN
$46
HIGH
$55
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TEVA TAPE
TEVA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $49.25 | $46.80 | 2025-02-14 | $37.04 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $51.28 | $48.03 | 2025-02-06 | $38.26 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $46.40 | $44.77 | 2025-01-29 | $39.07 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $41.51 | — | 2025-01-17 | $39.89 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $35.82 | $38.66 | 2025-01-09 | $36.22 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $48.43 | $42.33 | 2024-12-18 | $35.41 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $39.48 | $41.11 | 2024-12-04 | $37.85 | -4.3% | 48% | C |